Interestingly, selective analysis of the tumor-infiltrating T cells (of CD3+ cells instead of total cells) indicated that the ICOS/PD-1 combination therapy increased the percentage of cytotoxic CD8+ T cells and, at the same time, reduced the percentage of CD4+ effector cells. The gene discussed is CD8A; the disease is neoplasm.